Latest Hotspot

Ultomiris Approved by US to Treat Adults with NMOSD

28 March 2024
3 min read

Ultomiris (ravulizumab-cwvz), has received authorization from health authorities in the U.S. to be the inaugural and unique extended-duration C5 complement inhibitor indicated for therapy in grown-up individuals diagnosed with neuromyelitis optica spectrum disorder that is linked to the presence of anti-aquaporin-4 antibodies.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The US Food and Drug Administration granted authorization for the drug following the favorable data emanating from Stage III of the CHAMPION-NMOSD trial. This data was detailed in the medical journal Annals of Neurology. Within this clinical study, Ultomiris's efficacy was assessed against a control group using a placebo from the key Soliris PREVENT study.

Neuromyelitis Optica Spectrum Disorder (NMOSD) is an uncommon, severely incapacitating disorder of the autoimmune system, influencing the brain's, spine's, and optic nerves' functioning. Individuals affected by NMOSD commonly struggle with unpredictable flare-ups, marked by either the emergence of new neurological indicators or the exacerbation of pre-existing ones. These episodes, which can be acute and often reoccur, have the potential to cause lasting impairments. In the United States, it is projected that around 6,000 adult individuals are diagnosed with NMOSD.

Mayo Clinic expert Sean J. Pittock, MD, serving as the director for both the Multiple Sclerosis and Autoimmune Neurology Center and the Neuroimmunology Laboratory, remarked, “Blocking the activity of the C5 protein within the immune system's complement pathway has been established as an effective strategy to diminish the likelihood of NMOSD attacks. This works by preventing assaults on the healthy nerve cells located in the brain, spinal cord, and optic nerve.”

Marc Dunoyer, the CEO of Alexion Pharmaceuticals, commented, "Our company has consistently led in the NMOSD field, working tirelessly to shield patients from the dread of devastating, possibly fatal flare-ups. Leveraging the proven benefits of C5 inhibition for patients diagnosed with AQP4 Ab+ NMOSD, we are elated to provide an innovative, extended-duration therapy that could potentially avert flare-ups, administered via a manageable bi-monthly dosage regimen."

As per the findings from the CHAMPION-NMOSD clinical trial, the safety profile of Ultomiris was in agreement with outcomes from past study trials and its application in clinical settings, with no unforeseen safety concerns. The frequently encountered side effects involved COVID-19 infections, cephalalgia, dorsalgia, joint discomfort, and infections of the urinary system.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 文本, 应用程序, 表格

描述已自动生成

According to the data provided by the Synapse Database, As of March 26 2024, there are 47 investigational drugs for the C5 target, including 88 indications, 74 R&D institutions involved, with related clinical trials reaching 385, and as many as 196864 patents.

Ravulizumab-CWVZ has received approval for various therapeutic areas and has shown efficacy in treating a wide range of diseases. With its highest phase of approval globally and ongoing clinical trials in China, Ravulizumab-CWVZ holds promise for patients in need of effective treatment options.

图形用户界面, 文本, 应用程序

描述已自动生成

2023 FDA-Approved GPCR-Targeted New Drugs Roundup
Drug Highlight
11 min read
2023 FDA-Approved GPCR-Targeted New Drugs Roundup
28 March 2024
This article introduces the new drugs related to GPCR that were approved by the FDA in 2023.
Read →
FDA Approves OPSYNVI® as First Daily Combo Therapy for PAH
Latest Hotspot
3 min read
FDA Approves OPSYNVI® as First Daily Combo Therapy for PAH
27 March 2024
U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH).
Read →
OKYO Pharma's OK-101 Excels in Phase 2 Trial with Significant Dry Eye Relief
Latest Hotspot
3 min read
OKYO Pharma's OK-101 Excels in Phase 2 Trial with Significant Dry Eye Relief
27 March 2024
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101.
Read →
A Complete Guide to Searching Nitroglycerin on Synapse
Drug Insights
2 min read
A Complete Guide to Searching Nitroglycerin on Synapse
27 March 2024
Nitroglycerin, a minuscule molecule drug concocted by Merck, made its debut in the pharmaceutical market in 1983.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.